Implantable Miniature Telescope retains positive results in 5-year follow-up

The Implantable Miniature Telescope showed favorable safety and efficacy outcomes for treating end-stage age-related macular degeneration over the long term, particularly in patients younger than 75 years old, according to a study.

The prospective, open-label, multicenter clinical trial, a continuation of the 24-month IMT-002 study, evaluated 63 patients with the IMT (VisionCare Ophthalmic Technologies) 60 months after surgery, with 31 patients ranging from 65 to 74 years old in group 1 and 32 patients age 75 years or older in group 2.

At 24 months, mean improvement in best corrected distance visual acuity was 3.2 lines. At 60 months, mean improvement in best corrected distance visual acuity was 2.4 lines, with 62% of patients maintaining a two-line improvement. Retention of visual acuity gains was higher in group 1, with 58% maintaining three lines or more at 60 months.

Improvement in quality of life scores was significant in both groups, but higher in group 1.

Group 2 had a higher cumulative incidence of complications in 13 of 15 categories and more adverse events in 11 of 14 categories.

Mean endothelial cell density was 1,995 cell/mm² 3 months after implantation, with an acute loss of 20%. In the extension study, chronic loss was 3% per year, with less endothelial cell density loss in group 1 vs. group 2.

The IMT was removed from one patient in group 1 and 10 patients in group 2. – by Kristie L. Kahl

Disclosure: The authors report no relevant financial disclosures.

Published by:

Sources/Disclosures

Collapse

Source:

Boyer D, et al. Clin Ophthalmol. 2015;doi:10.2147/OPTH.S86208.